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Summary 
Background: Some observational studies indicate an asso-
ciation of 25-hydroxy vitamin D (25(OH)D) insufficiency
and atherogenic cholesterol concentrations. The aim of
this study was to investigate relationship between 25(OH)D
concentrations and lipid parameters in end stage renal
disease (ESRD) patients, separately for predialysis, hemo -
dialysis and peritoneal dialysis patients.
Methods: We have adjusted 25(OH)D concentrations for
seasonal variability with cosinor analysis, and performed all
further analysis using these corrected 25(OH)D concentra-
tions. Concentrations of 25(OH)D and the lipid parameters
were determined in 214 ESRD patients and 50 control
group participants. The analysis included the measurement
of 25(OH)D by HPLC, apolipoprotein (Apo) AI, ApoB and
Lp(a) by nephelometry, total cholesterol (TC), high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C) and triglyceride (TG) by spectropho-
tometry and manually calculated ApoB/ApoAI and
LDL-C/HDL-C ratio.
Results: ESRD patients with adjusted 25(OH)D concentra-
tions of  50 nmol/L had significantly higher TC (P =
0.005) and ApoAI (P = 0.049). Significantly higher HDL-
C (P = 0.011) and ApoAI (P = 0.020) were found in
Kratak sadr`aj
Uvod: Opservacione studije ukazuju na povezanost nedo -
statka 25-hidroksi vitamin D (25(OH)D) i koncentracija
aterogenog holesterola. Cilj ove studije bio je da se ispita
me|usobna povezanost 25(OH)D i lipidnih parametara
kod bolesnika sa krajnjim stadijumom bolesti bubrega
(ESRD) posebno kod predijaliznih, bolesnika na hemodija -
lizi i peritonalnoj dijalizi.
Metode: Podesili smo koncentracije 25(OH)D za sezonsku
varijaciju koriste}i kosinor analizu, i u daljem ispitivanju smo
koristili korigovane koncentracije 25(OH)D. Koncen tracije
25(OH)D i lipidnih parametara su odre|ene za 214 ESRD
bolesnika i 50 u~esnika kontrolne grupe. Analizirali smo
koncentracije 25(OH)D metodom HPLC, apolipoproteina
(Apo) AI, ApoB i Lp(a) nefelometrijski, ukupnog hole sterola
(TC), lipoproteina velike gustine (HDL-C), lipoproteina
male gustine (LDL-C) i triglicerida (TG) spektro fotometrijski
i ru~no prera~unavali indekse ApoB/ApoAI i LDL-C/HDL-
C.
Rezultati: ESRD bolesnici sa korigovanim 25(OH)D  50
nmol/L su imali zna~ajno vi{i TC (P = 0,005) i ApoAI (P =
0,049). Zna~ajno vi{e koncentracije HDL-C (P = 0,011) i
ApoAI (P = 0,020) smo dobili kod hemodijaliznih boles -
nika sa 25(OH)D koncentracijama  50 nmol/L. Ostali
List of abbreviations: ApoAI, apolipoprotein AI; ApoB, apolipo -
protein B; CVD, cardiovascular disease; CAPD, patients on con-
tinuous ambulatory peritoneal dialysis; CG, control group; DBP,
vitamin D binding protein; ESRD, end stage renal disease; GFR,
glomerular filtration rate; HD, hemodialysis patients; HDL-C,
high-density lipoprotein cholesterol; KDIGO, Kidney Disease
Improving Global Outcomes; Lp(a), lipoprotein(a); LDL-C, low-
density lipoprotein cholesterol; PD, predialysis patients; TC, total
cholesterol; TG, triglycerides; 25(OH)D, 25-hydroxy vitamin D.
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Introduction
End stage renal disease (ESRD) is associated
with apolipoprotein abnormalities and dyslipidemia
(1–3). Altered lipid metabolism is usually deemed to
be a consequence of renal disease, but a large body
of clinical and experimental studies support the fact
that there is inter-dependence of vitamin D levels with
serum lipid profiles in ESRD patients (4). Some inves-
tigations have proposed that there is potential
association of vitamin D binding protein (DBP) with
lipoproteins in chronic renal failure, but also that sig-
nificant urinary DBP losses contributing to vitamin D
deficiency (5). 
Literature data suggests that high 25-hydroxy
vitamin D (25(OH)D) concentrations have been
strongly correlated with an optimal concentrations of
lipid parameters, but only a few studies take into
account ESRD patients and dialysis type effects on
vitamin D relationship with lipids (5, 6). In support of
this, in vitro studies have proved that 25(OH)D
inhibits 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase (HMGCoA reductase), the major choles-
terol synthesis enzyme and therefore reduces total
cholesterol level (7). Vitamin D deficiency is an
increasingly common diagnosis in ESRD patients and
low concentrations of 25(OH)D are assocciated with
many diseases, including atherogenic cholesterol
concentrations. Major problem for adequate assess-
ment of vitamin D level and its relationship with lipids
lies in the fact that seasonal variation may reduce the
validity of 25(OH)D as a biomarker of overall vitamin
D status. It is therefore important to implement a sea-
sonal adjustment to correct measured 25(OH)D
concentrations.
Recommendation of updated clinical practice
guideline for lipid management in chronic kidney dis-
ease (KDIGO – Kidney Disease Improving Global
Outcomes) is to evaluate lipid status by measuring
total cholesterol (TC), high-density lipoprotein choles-
terol (HDL-C), low-density lipoprotein cholesterol
(LDL-C) and triglycerides (TG) (8). The most impor-
tant abnormalities are an increase in serum LDL-C
and TG, and a decrease in HDL-C concentrations,
while TC concentrations are mostly in the normal
limits. On the other hand, renal dyslipidemia is cha ra -
cterized to a greater extent by abnormal apo lipo -
protein rather than recommended lipid parameters
(9). Moreover, ESRD patients usually have decreased
concentrations of apolipoprotein A (ApoA) containing
lipoproteins (apoAI) and increased concentrations of
apolipoprotein B (ApoB) and lipo protein(a) (Lp(a))
(10, 11). These changes consequently could lead to
cardiovascular complications. Recommended therapy
with statins could improve lipid and apolipoprotein
status in ESRD patients, but more recent studies have
explained the benefit of vitamin D therapy on this
issue in relation to cardiovascular disease (CVD) (2,
12, 13).
Best screening for vitamin D status in ESRD
patients is measurement of 25(OH)D (12). On the
basis of recent recommendations, a 25(OH)D con-
centration ranging from 50 to 75 nmol/L was defined
as vitamin D repletion, a 25(OH)D concentration of
< 50 nmol/L as vitamin D insufficiency and a
25(OH)D concentration of < 25 nmol/L as severe
vitamin D deficiency (14). Because ESRD patients
often take vitamin D supplements for therapeutic pur-
pose and consequently rarely exhibit severe vitamin D
deficiency, in this study we have chosen concentration
of 50 nmol/L for 25(OH)D as debatable. Never -
theless, a recent publication has pointed out that
there is no agreement on the reference ranges for
serum total 25(OH)D, which represents a problem in
patient categorization (15).
The aim of this study was to evaluate the con-
centrations of TC, HDL-C, LDL-C, TG, ApoAI, ApoB
and Lp(a) in ESRD patients in relation to control
group (CG) participants and in relation to 25(OH)D
concentrations (< 50 nmol/L and  50 nmol/L). In
addition, we have examined the analyzed lipid param-
eters separately in predialysis patients (PD), chronic
hemodialysis patients (HD) and in patients on contin-
uous ambulatory peritoneal dialysis (CAPD). We
intended to investigate if there were more expressive
changes in the ApoB/ApoAI and LDL-C/HDL-C ratio
in respect of individual lipid parameters, as well as
25(OH)D concentration. 
hemodialysis patients with the 25(OH)D concentrations of
 50 nmol/L. The other analyzed lipid parameters differed
significantly between predialysis, hemodialysis and peri-
toneal dialysis patients with 25(OH)D concentrations of <
50 nmol/L. 
Conclusions: Our study indicate the significant relationship
between 25(OH)D repletion and optimal concentrations of
lipid parameters in ESRD patients. Further research is nec-
essary to explain whether joint evaluation of vitamin D
status and lipid abnormalities could improve cardiovascular
outcome in ESRD patients. 
Keywords: lipid parameters, 25-hydroxy vitamin D, end
stage renal disease, dialysis
analizirani lipidni parametri su bili zna~ajno razli~iti izme|u
ana liziranih grupa bolesnika sa 25(OH)D koncentracijama
< 50 nmol/L.
Zaklju~ak: Na{a studija ukazuje na zna~ajnu povezanost
dovoljnih nivoa 25(OH)D i optimalnih koncentracija lipid-
nih parametara kod ESRD bolesnika. Potrebna su dalja
istra`ivanja da bi se objasnilo da li zajedni~ka procena sta-
tusa vitamina D i lipidnih abnormalnosti mogu da pobolj -
{aju kardiovaskularni ishod kod ESRD bolesnika.
Klju~ne re~i: lipidni parametri, 25-hidroksi vitamin D,
krajnji stadijum bolesti bubrega, dijaliza
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Materials and Methods
Study design and sample collection
This study was conducted between February
and July 2013, on PD (N = 33), HD (N = 89) and
CAPD (N = 92) who were admitted and have been
treated at the Clinic of Nephrology and Urology,
Clinical Center of Serbia. All patients gave informed
consent to participate in the study, which was
approved by the Ethics Committee of the University
Clinical Center, Belgrade. The CG participants (N =
50) were recruited among healthy Serbian volunteers.
Selection was based on the results of laboratory tests
(within the reference intervals used in the Department
of Polyclinic Laboratory Diagnostics, the Center for
Medical Biochemistry, the Clinical Center of Serbia),
and the completed questionnaire before phlebotomy.
Based on the questionnaire, we selected people with
the absence of chronic or acute illness and without
the use of pharmacologically active substances.
Median age for PD, HD and CAPD group of
patients was 49 years (range: 24–76), 52 years
(range: 26–74) and 54 years (range: 32–79), respec-
tively. Median age for the CG was 50 years (range:
25–70). According to the KDIGO guideline and
glomerular filtration rate (GFR) all the analyzed
patients were categorized as G5 (Kidney failure) (16).
All PD had a creatinine clearance < 15 mL × min−1
× (1.73 m2)−1 and required maintenance dialysis
within three months after entering the study. All HD
underwent chronic haemodialysis treatment three
times a week and the median time since the begin-
ning of haemodialysis was 72 months. Median
duration of CAPD was 22 months. Of all the studied
patients, 9 PD, 43 HD and 25 CAPD had received
oral 1 -OH D3 (0.25 mg/day). Exclusion criteria for
this study were: diabetes mellitus, known or suspect-
ed liver disease and immunosuppressive therapy.
Keeping in mind the seasonal variability of vitamin D
concentrations, we adjusted the measured levels of
25(OH)D for seasonal differences.
Methods
Blood samples were drawn via antecubital veni -
puncture after an overnight fast, in PD patients when
they were on routine laboratory examinations and in
HD patients blood was drawn prior to dialysis. CAPD
patients continued their dialysis during sampling. 
Serum 25(OH)D concentrations were deter-
mined by chromatography, using reversed phase
HPLC technique with UV detection on 265 nm
(ChromLineR Clinical HPLC software Version 4.20B,
Chromsystems Instruments & Chemicals GmbH,
Gräfelfing, Germany). We used commercial quality
control samples to perform precision testing. Total
precision for internal quality control samples with
avarage 25(OH)D concentrations of 72.4 nmol/L
and 222 nmol/L were 4.7% and 4.0%, respectively.
The cosinor model was applied to baseline data, and
the corrected values were used for all further analysis.
Since vitamin D concentrations follow a sinusoidal
seasonal pattern, we fitted a cosinor model to base-
line monthly 25(OH)D concentrations. Then, we
estimated each patient's adjusted 25(OH)D concen-
tration. Period of measurement was 6 months (from
February to July). To adjust seasonal 25(OH)D varia-
tion according to each patients’ characteristics, we
included covariates in the model (gender, age).
Sine curve is defined with an amplitude and a
phase. Amplitude (A) is defined as the maximum dis-
tance of the sine wave from the mean. One can
estimate the seasonal variation based on the ampli-
tude. The phase is defined as the position of the peak
on the x axis,which is equivalent to the month of the
highest 25(OH)D concentration (17). 
Concentrations of ApoAI, ApoB and Lp(a) were
measured by an immunonephelometric method on a
Behring Nephelometer II analyzer (Siemens Health -
care GmbH, Erlangen, Germany). Total cholesterol,
HDL-C, LDL-C and TG were determined using spec-
trophotometric commercial assays on Olympus
AU2700 analyser (Beckman Coulter Diagnostics,
Hamburg, Germany). LDL-C concentrations were cal-
culated by the Friedewald equation, except when
triglycerides were > 4.45 mmol/L, when we used
direct spectrophotometric assay. 
We used a set of commercial quality control
samples for internal quality control: 25-OH-Vitamin
D3/D2 Serum Control Level I and Level II for
25(OH)D (Chromsystems Instruments & Chemicals
GmbH, Gräfelfing, Germany), Apolipoprotein Control
Serum CHD (human) and N Lp(a) Control SY for
ApoAI, ApoB and Lp(a) (Siemens Healthcare GmbH,
Erlangen, Germany) and OLY 1 and OLY 2 Control
Serum for TC, HDL-C, LDL-C and TG (Beckman
Coulter Diagnostics, Hamburg, Germany). Intra-assay
CVs for all measured parameters were < 5%.
Statistical analysis
We used one-sample Kolmogorov-Smirnov and
Shapiro-Wilk test to analyze normality of distributions
of the analyzed parameters. Descriptive measures are
expressed as median and interquartile range (IQR).
Kruskall-Walis independant samples test was applied
to compare the concentration of the analyzed apo -
lipoproteins and lipids between patients and CG, to
compare the apolipoproteins and lipids concentration
regarding the 25(OH)D status and to detect differ-
ences in apolipoprotein and lipid concentration
between PD, HD and CAPD patients. A value of P <
0.05 was considered significant. For cosinor analysis
we used R statistical softwer (version R 3.5.1) (18).
Statistical analyses were performed with SPSS version
21.0 (IBM, Chicago, USA).
Results
Figure 1 represents the measured 25(OH)D
concentrations at baseline according to the month of
blood draw. Sinusoidal model closely approximated
measured 25(OH)D concentrations. 
A fitted line from an unadjusted cosinor model
is overlaid on the baseline measured values. The mean
(annual) 25(OH)D concentration obtained from the
model was 38.4 nmol/L (95% CI:36.8–39.9), and
the peak-trough difference in annual mean was 38.7
nmol/L (95% CI: 34.2–43.2). A trough occurred
between February and March while a peak was
between May and June. The amplitude was 19.3
nmol/L, which is equivalent to 49.6% of the annual
mean. After adjustment for patients’ gender and age,
the predicted mean annual vitamin D concentration
was 42.2 nmol/L (95% CI:34.3–49.1).
We used these corrected 25(OH)D concentra-
tions for all further analysis. We compared the
312 Milinkovi} et al.: Lipid status and 25-hydroxy vitamin D in renal patients
Figure 1 Seasonality of 25(OH)D concentrations in 214 end stage renal disease patients at base line. The overlaid curve is
from an unadjusted cosinor model and shows the annual mean 25(OH)D concentration according to month of the year.
Table I Comparison of the lipid parameters between ESRD patients and CG participants and between subgroups based on
adjusted 25(OH)D concentrations for seasonal variation (< 50 nmol/L and ≥ 50 nmol/L) in ESRD patients
Lipid parameter CGN = 50
ESRD patients
P< 50 nmol/L
N = 167
 50 nmol/L
N = 47
25(OH)D, nmol/L 73.5 (67.0–81.8) 35.1 (28.9–41.9) 52.9 (48.9–59.9) < 0.001a, b
TC, mmol/L 4.32 (4.12–4.65) 5.98 (5.03–6.30) 6.22 (5.98–6.55) 0.003a, 0.005b
HDL-C, mmol/L 1.53 (1.38–1.67) 0.82 (0.68–0.98) 0.88 (0.73–0.98) 0.039a, 0.429b
LDL-C, mmol/L 2.31 (2.18–2.46) 5.01 (4.63–5.42) 4.99 (4.65–5.14) < 0.001a, 0.142b
TG, mmol/L 1.09 (0.91–1.39) 2.13 (1.95–2.78) 2.14 (1.962.54) 0.003a, 0.808b
ApoB, g/L 0.93 (0.75–1.12) 1.47 (1.31–1.67) 1.49 (1.43–1.67) 0.072a, 0.309b
ApoAI, g/L 1.89 (1.47–2.09) 1.71 (1.43–1.92) 1.80 (1.63–1.99) 0.046a, 0.049b
Lp(a), g/L 0.21 (0.17–0.24) 0.37 (0.29–0.45) 0.34 (0.30–0.42) 0.006a, 0.820b
ApoB/ApoAI 0.53 (0.39–0.65) 0.87 (0.73–1.11) 0.87 (0.75–0.95) 0.011a, 0.419b
LDL–C/HDL–C 1.53 (1.36–1.71) 6.11 (5.14–7.54) 5.55 (4.94–6.57) < 0.001a, 0.256
basignificant difference between ESRD and CG; bsignificant difference between ESRD subgroups 
Data are presented as median and interquartile range (IQR); Mann–Whitney U test for independant samples; ApoAI,
Apolipoprotein AI; ApoB, apolipoprotein B; CI, confidence interval; CG, Control Group; ESRD, end stage renal disease;
HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; N, number of subjects; TG, tryglicerides; TC, total cholesterol;
25(OH)D, 25-hydroxy vitamin D
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concentrations of the analyzed parameters between
ESRD and CG and we examined divergence in the
analyzed lipid and apolipoprotein parameters in ESRD
patients divided according to the clinically significant
concentrations of 25(OH)D (those with < 50 nmol/L
and  50 nmol/L) (Table I). 
We found significantly higher concentrations of
TC (P =0.003), LDL-C (P < 0.001), TG (P = 0.003),
Lp(a) (P = 0.006), ApoB/ApoAI (P = 0.011) and
LDL-C/HDL-C ratio (P < 0.001), and significantly
lower concentrations of HDL-C (P = 0.039) and
ApoAI (P = 0.046) in ESRD patients compared to CG
(Table I). When we have compared lipid parameters
Figure 2 Impact of the maintenance dialysis and dialysis mode in relation to 25-hydroxy vitamin D concentrations on lipid
parameters: A: TC, total cholesterol; B: HDL-C, high density lipoprotein; C: TG, tryglicerides; D: ApoB, apolipoprotein B; E:
ApoAI, apolipoprotein AI; F: Lp(a), lipoprotein (a); G: ApoB/ApoAI ratio and H: LDL-C/HDL-C ratio; PD, predialysis patients;
HD, hemodialysis patients; CAPD, patients on continuous ambulatory peritoneal dialysis.
x⎯
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concentrations between ESRD subgroups, we have
found significantly higher TC (P = 0.005) and ApoAI
(P = 0.049) in ESRD with 25(OH)D concentrations 
50 nmol/L (Table I).
In this study, we considered possible effect of
dialysis mode on the analysed lipid parameters in
relation to corrected 25(OH)D concentrations (< 50
nmol/L and  50 nmol/L) (Figure 2). 
After adjustment of 25(OH)D concentrations for
seasonal variation we found that only one PD patient
had 25(OH)D concentration above used cut off in
this study (55.1 nmol/L). Median and IQR for
25(OH)D concentrations < 50 nmol/L in PD patients
was 38.9 nmol/L (33.1–42.1). Median and IQR for
25(OH)D concentrations < 50 nmol/L and  50
nmol/L in HD and CAPD patients were: 34.1 nmol/L
(28.9–39.1), 53.1 nmol/L (48.8–55.7), 33.9
nmol/L (26.7–41.9) and 52.9 nmol/L (48.9–60.9),
respectively.
When we compared lipid parameters in HD
patients according to their 25(OH)D status, we found
significantly higher HDL-C (0.97 vs. 0.78 mmol/L, P
= 0.011) and ApoAI (1.91 vs. 1.70 g/L, P = 0.020)
in 25(OH)D  50 nmol/L HD group. The other ana-
lyzed lipid parameters did not differ significantly
re garding the 25(OH)D concentrations in the studied
groups of patients. In groups with adjusted 25(OH)
concentrations  50 nmol/L, we found significantly
higher HDL-C (0.97 vs. 0.77 mmol/L, P = 0.012) in
HD patients compared to CAPD group (Figure 2). 
However, we have found significant impact of
dialysis mode in groups with 25(OH)D concentrations
< 50 nmol/L (Figure 2). We have found significantly
lower ApoB (0.99 vs. 1.67 g/L, P < 0.001), Lp(a)
(0.29 vs. 0.43 g/L, P < 0.001), ApoB/ApoAI (0.65
vs. 1.06, P < 0.001) and LDL-C/HDL-C (5.27 vs.
6.52, P < 0.001), and significantly higher HDL-C
(0.98 vs. 0.78, P < 0.001) in PD patients compared
to HD group. In addition, PD patients have had sig-
nificantly lower TC (4.89 vs. 6.23 mmol/L, P <
0.001), TG (1.94 vs. 2.42 mmol/L, P < 0.001),
ApoB (0.99 vs. 1.46 g/L, P < 0.001), Lp(a) (0.29 vs.
0.32 g/L, P = 0.11) and LDL-C/HDL-C (5.27 vs.
5.98, P = 0.041), and significantly higher HDL-C
(0.98 vs. 0.78 mmol/L, P < 0.001) in comparison
with CAPD group, respectively. When we compared
HD and CAPD groups with 25(OH)D D concentra-
tions < 50 nmol/L, we have found significantly lower
TC (5.46 vs. 6.23 mmol/L, P < 0.001), TG (2.02 vs.
2.42 mmol/L, P < 0.001), and significantly higher
ApoB (1.67 vs. 1.46 g/L, P < 0.001), Lp(a) (0.43 vs.
0.32 g/L, P = 0.032) and ApoB/ApoAI (1.06 vs.
0.83, P < 0.001). There was no difference in lipid
parameters concentrations in relation to 25(OH)D
status in CAPD patients. 
Discussion
The main finding of our study is that there is a
significant relationship between serum 25(OH)D con-
centrations and lipid status and that adequate
25(OH)D concentrations contribute to favorable reg-
ulation of lipid status parameters in ESRD patients.
While literature data are still controversial about the
protective role of 25(OH)D concentrations against
CVD, there is an unequivocally confirmed relation
between lipid parameters and 25(OH)D concentra-
tions in ESRD patients (19–21). However, there is no
definitive conclusion on the effect of vitamin D sup-
plementation on lipid concentrations. 25(OH)D
concentrations vary seasonally due to highly variable
exposure to sunlight, which is why single measure-
ments usually poorly reflect long-term 25(OH)D
status. Circulating 25(OH)D concentrations differ
substantially over the calendar year, within individuals
and general population. Normally the concentrations
are lowest at the end of winter and highest at the end
of summer. This is likely due to seasonal differences
in ultraviolet light exposure (21). Nevertheless, our
study is the first to investigate relationship between
adjusted 25(OH)D and lipid status for PD and dialysis
patients, with respect to dialysis mode. 
When we analyzed overall ESRD patients relative
to the CG, resulting lipid concentrations were in
agreement with KDIGO recommendations, except TC
concentrations wich were significantly higher in ESRD
patients compared to the CG. In support of our find-
ings, several previous studies showed that high
concentrations of TC might play an important role in
the pathogenesis and progression of kidney disease
(1–3). Significantly higher TC concentrations in
25(OH)D  50 nmol/L, could support the fact that
there was a tendency towards an increase in TC con-
centrations with supplementation of vitamin D and
that vitamin D may have potentially unfavorable
effects on lipoprotein metabolism (19). Opposite to
this finding was the Wienstock-Guttman et al. (7)
study that discusses sufficient vitamin D levels and its
impact on correction of high TC in patients with mul-
tiple sclerosis. The question is whether there is a
different vitamin D-lipid interdependence concerning
different pathophisiology of patients. In this study,
prior to measuring 25(OH)D concentrations, we car-
ried out deproteinisation as a standard preanalitical
phase of HPLC procedure, so we principally excluded
any effect of DBP on 25(OH)D concentrations.
However, it still remains possible that DBP affects lipid
concentration in ESRD patients. This remains for
future studies to reveal. Based on currently available
literature, the increase in 25(OH)D concentration
from insufficient to optimal range and its effects on
lipid status have been varied and inconclusive (4, 10,
13, 23). Unchanged Lp(a) concentration in different
25(OH)D groups could implicate that this lipoprotein
is not clinically significant in prediction of CVD pro-
gression and complications in ESRD patients, except
if considered with adjustment for dialysis mode. We
did not found significant difference in LDL-C concen-
trations regarding the 25(OH)D concentrations.
However, we cannot exclude the formation of qualita-
tively different molecules from normal LDL-C
(small-dense LDL-C, oxidized LDL-C). Previous data
indicate that there is a »grey zone« for the Friedewald
equation for TG concentrations around 4.45
mmoL/L, that tends to underestimate LDL-C in the
setting of high TG concentrations (24, 25). This is
especially critical at low LDL-C concentrations, which
could result in undertreatment of high-risk patients. In
this study we had only 6% of CAPD patients (total 6
of 92 patients) that had TG concentration above 4.45
mmol/L, but did not have low LDL-C (concentrations
from 4.22 to 5.78 mmol/L). There are controversial
facts about clinical significance of lipid ratios for pre-
diction of CVD, but generally overall ESRD patients
were not studied. However, some studies reported
that ApoB/ApoAI ratio is better than LDL-C, and that
ApoB/ApoAI increase indicates an increased risk of
CVD and may provide some useful information in the
differential diagnosis (26, 27). Our study results sup-
port these findings because even though we did not
found any difference in ApoB concentrations in ESRD
patients regarding 25(OH)D concentrations, nor
between ESRD and CG patients, our data showed
that ApoB/ApoAI and LDL-C/HDL-C ratio were sig-
nificantly higher in ESRD patients compared to CG,
regardless of 25(OH)D concentrations. Lipid ratios
could be an independent cardiovascular risk indica-
tors in ESRD patients, but future studies need to
evaluate the potential advantage of integrating them
into routine clinical practice. 
In addition, we analyzed lipid parameters in rela-
tion to 25(OH)D concentrations (< 50 nmol/L and 
50 nmol/L) separately for PD, HD and CAPD
patients. Main restriction of this study was that after
adjustment of 25(OH) concentrations for seasonal
variation, we found only one PD patient that had
25(OH)D concentration  50 nmol/L. So we could
not present reliable relationship between lipids and
25(OH)D concentrations  50 nmol/L in this particu-
lar group. However, lower TC, TG, ApoB, Lp(a) and
lipid ratios in PD patients with 25(OH)D < 50 nmol/L
regarding the dialysis mode confirm undesirable
effect of dialysis on lipid status. Ko et al. reported that
lower 25(OH)D concentrations can influence the car-
diovascular as well as all-cause mortality in PD
patients and that 25(OH)D level could be an equal
predictor of patient outcomes in PD and HD patients
(28). Contrary to our findings of significantly higher
ApoB concentrations and ApoB/ApoAI ratio in the
analysed HD patients with  50 nmol/L 25(OH)D
concentrations compared to 25(OH)D < 50 nmol/L
HD patients, some previous studies have presented
positive effect of vitamin D supplementation on the
lipid parameters of regular hemodialysis patients (29–
31). Our study results could indicate the additional
factors that may affect lipoprotein metabolism in dial-
ysis patients such as treatment with erythropoietin,
L-carnitine supplementation, use of low molecular
weight heparin and high-flux dialysis. There is evi-
dence that CAPD patients exhibit a more atherogenic
concentrations of lipid parameters than HD patients,
but we found no significant impact of 25(OH)D on
the lipid status of the analysed CAPD patients (32).
Unexpected result in this study was higher HDL-C in
HD patients in comparison with CAPD vitamin D suf-
ficient group, that may indicate the HDL-C
dys function in CAPD patients. This is in line with the
results of Moradi et al. (33) who pointed out that this
can further exacerbate the cardiovascular disease
burden. 
Observation of our study of the inconsiderable
impact of the 25(OH)D concentrations on other lipid
status parameters in CAPD patients could point to
unevenly peritoneal loss of both lipids and vitamin D.
However, other facts should be taken into account
such as the duration of peritoneal dialysis procedure,
vitamin D analogs concentration, and patient’s age.
Despite the recent explaination that CAPD patients
have better quality of life, this patients may present a
further increase of CVD risk if not adequately mo -
nitored (33–35). After using cosinor analysis for
seasonal correction of 25(OH)D concentrations, we
found a trend of normalization 25(OH)D values,
which also refflected its relationship with lipids. More
data is needed to improve clinical utility of seasonally
adjusted vitamin D level regarding lipid status in
ESRD patients. 
This study has some limitations. Design of this
study was cross-sectional and we were not able to
analyze the long-term effects of vitamin D supple-
mentation on lipid parameters in the studied
population, although we realize that an interventional
study could better explain the causal relationship
between variables. Main omission of this study is that
we did not measure DBP and evaluate its possible
effect on vitamin D and lipid status in studied ESRD
patients. In addition, we did not evaluate any inflam-
matory markers, although these markers have
physiological relationships with lipid abnormalities.
Potential confounding of therapy with cholesterol-
lowering agents was not examined and we had small
number of patients who were on therapy including
vitamin D suplementation. 
Conclusion
One important clinical consideration and con-
clusion of our study is that lipids and lipoproteins as
well as lipid ratio parameters is preferably to con-
trolled in relation with 25(OH)D concentrations and
separately for PD and dialysis patients. In addition,
there is noticeable effect of dialysis mode on lipid
parameters. This study findings could be useful for
J Med Biochem 2020; 39 (3) 315
further vitamin D suplementation in ESRD patients in
relation to lipid menagement, but further research is
necessary to explain whether joint evaluation of
25(OH)D status and lipid abnormalities could
improve cardiovascular outcome in ESRD patients. 
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